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Abstract 
 
The aim of this study was to evaluate the performance of a molecular assay 
for quantitation of Epstein-Barr virus (EBV) DNA based on real-time PCR, and 
to determine EBV DNA levels in EDTA whole blood samples derived from 
different groups of patients. Following a manual DNA extraction protocol, real-
time PCR was performed using the LightCycler EBV Quantification Kit, which 
demonstrated sufficient accuracy and linearity. Coefficients of variations were 
found to be between 6 and 42% and 5 and 34%, respectively, for interassay 
and intra-assay variations.  
In clinical specimens, EBV DNA was detected in all patients with acute EBV 
infection (n=34), in one of 25 adults with past EBV infection, in 16 out of 25 
(64%) anti-HIV antibody positive persons, in 10 out of 25 (40%) solid organ 
transplant recipients, and in none of the 23 infants without history of EBV 
infection. When EBV DNA levels in positive specimens were compared 
between different groups, statistically significant differences were not found. 
The LightCycler EBV Quantification Kit was found to be useful for 
determination of EBV DNA levels in EDTA whole blood. 
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1. Introduction 
 
Epstein-Barr virus (EBV) is a human herpesvirus classified in 
Lymphocryptovirus genus of the Gammaherpesviridae subfamily.  EBV infects 
B-lymphocytes and oropharyngeal epithelial cells. After primary infection, EBV 
establishes life-long latency. The expression of specific latency-associated 
genes determines whether the virus will be maintained in a latent state or turn 
into active viral replication (Cohen et al., 2000; Johannsen et al., 2005). 
Epstein-Barr virus is the etiologic agent of infectious mononucleosis but 
may also act as an oncogene associated with nasopharyngeal carcinoma and 
Burkitt`s lymphoma. In the immunocompromised host, EBV is associated with 
posttransplant lymphoproliferative disorders or AIDS-related lymphomas.  
Posttransplant lymphoproliferative disorders may occur in 1-20% of transplant 
recipients depending on several issues including type of transplantation, 
intensity and duration of immunosuppressive therapy and CMV infection 
(Andreone et al., 2003).  
Diagnosis of EBV infection is usually based on serological testing and 
clinical presentation. However, serology may be unreliable in 
immunocompromised patients (Verschuuren et al., 2003). In these patients, 
the diagnostic method should be able to differentiate latency from disease. 
Recently, distinct patterns of viral gene expression at the RNA level were 
described in EBV-associated diseases (Stevens et al., 2005). Although 
profiling EBV mRNA expression might be of interest, these methods could be 
demanding for routine clinical use.  
Molecular detection of EBV DNA has been shown to be useful for 
monitoring of dynamic EBV-load fluctuations in immunocompromised patients 
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(Bai et al., 1997; Meerbach et al., 2001, Stevens et al., 2001a). The EBV DNA 
level has been found to correlate with the severity of illness (Rowe et al., 
1997; van Esser et al., 2001). Molecular assays for detection of EBV DNA are 
usually based on home-designed protocols (Baldanti et al., 2000; Limaye et 
al., 1999; Riddler et al., 1994). These assays involve commonly laborious 
extraction protocols and do not include appropriate postamplification detection 
methods. Some of these methods lack inclusion of an internal control and 
they usually are not designed for accurate quantitation of EBV DNA. Recently, 
molecular assays for detection of EBV DNA based on real-time PCR have 
been reported (Brengel-Pesce et al., 2002; Jebbink et al., 2003; Kimura et al., 
1999; Niesters., 2000; Stevens et al., 2002a). Compared to conventional 
PCR-based assays, real-time PCR offers several important advantages. It 
combines amplification of target DNA with detection of amplification products 
in the same closed reaction vessel. Therefore, the potential for contamination 
is reduced significantly. With real-time PCR assays, the analytical turnaround 
time is significantly shorter than that required for conventional PCR assays. In 
contrast to conventional PCR, real-time PCR allows for log-phase analysis. 
Therefore, the quantitation range for real-time PCR assays is significantly 
broader than that for conventional PCR assays. 
Recently, the LightCycler EBV Quantification Kit (Roche Diagnostics 
GmbH, Roche Applied Science, Mannheim, Germany) has been introduced.  
This assay is based on real-time PCR employing the hybridization probes 
technology, and it contains an internal control in order to detect possible 
inhibition. Although this kit is intended for quantitative detection of EBV DNA 
in various human samples (whole blood, plasma, cerebrospinal fluid, cell 
culture), EBV DNA isolated from EDTA whole blood showed better test 
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sensitivity when compared to plasma. EDTA whole blood has been found to 
reflect the viral load in the defined unit of circulation better than any other 
matrices (Stevens et al 2001a).  
The aim of this study was to evaluate the performance of a commercially 
available real-time PCR assay for quantitation of EBV DNA. Accuracy was 
tested with the Quality Control for Molecular Dianostics 2002 Epstein-Barr 
Virus Proficiency Panel and linearity with a dilution series of a routine EBV 
DNA positive sample. Both interassay and intra-assay variations were 
determined. The utility of the molecular assay for quantitation of EBV DNA in 
EDTA whole blood was evaluated on clinical samples derived from five 
groups of patients with different clinical and serological presentation of 
Epstein-Barr virus infection. Although there are similar reports concerning 
EBV DNA quantitative detection in EBV-related diseases with different real-
time PCR tests, the data on LightCycler EBV Quantification Kit are 
uncommon.    
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2. Materials and Methods 
 
2.1. Molecular Assay 
 
Blood was collected using 3.5 ml-EDTA tubes (BD, Franklin, Lakes, NJ, 
USA). Within 24 hours after blood collection, EBV DNA was isolated with the 
QIAamp blood Mini kit (Qiagen, Hilden, Germany) according to the 
manufacturer´s package insert. The input volume was 200 µl. For each 
sample, 10 µl of an EBV DNA quantitative internal standard was added to 200 
µl of lysis reagent. Extracted DNA was eluted in 100 µl of elution buffer. 
Real-time PCR was carried out using the LightCycler EBV Quantification 
Kit  on the LightCycler Instrument, version 1, Software version 3.3, according 
to the manufacturer's package insert. The test employs hybridization probes 
to detect a gene fragment encoding a single copy of EBV gene EBNA 1. The 
primers and probes in the kit are specific for amplification and detection of the 
EBV DNA, so unspecific amplification of other agents is avoided (Auer et al., 
2002). The LightCycler capillaries were filled with 15 µl of master mix and 5 µl 
of extracted DNA. Three external controls (negative, low positive, and high 
positive) were included in each run. 
 
2.2. Study Design 
 
In the first step, the accuracy of the molecular assay was determined with 
original samples (n=8) of the Quality Control for Molecular Diagnostics 
(QCMD) 2002 Epstein Barr virus proficiency panel. This panel contained 
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samples with different concentrations of EBV DNA copies per ml (range, 1.0 X 
102 to 5.0 X 104) as well as a negative control. 
In the second step, the linearity of the molecular assay was determined.  A 
routine clinical EDTA whole blood sample with high viral load was used for the 
determination of linearity. A dilution series (0.5 log steps, i.e., 1:3.16 dilutions) 
was prepared by using EBV DNA negative-EDTA whole blood. Each dilution 
was analyzed three times and the mean EBV DNA copy number of each 
sample was determined. 
In the third step, the interassay variation of the molecular assay was 
determined. In eight clinical routine samples that contained different 
concentrations of EBV DNA (ranging from 9.6 X 103 to 2.3 X 104 copies per 
ml), DNA was re-isolated five times and tested once on each of five different 
days. 
In the fourth step, the intra-assay variation of the molecular assay was 
determined. Four clinical routine samples with different EBV DNA 
concentrations ranging from 3.4 X 103 to 2.0 X 104 copies per ml were 
aliquoted, and each aliquot was tested five times in one run.  
 
2.3. Clinical Samples 
 
A total of 132 clinical samples were studied. All samples were obtained 
from patients for routine clinical diagnosis. The patients were diagnosed and 
treated at the Dr Fran Mihaljević University Hospital for Infectious Diseases, 
Zagreb, Croatia, between January 2003 and October 2004. The local ethics 
committee approved the study.  
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Samples were obtained from five different groups of patients. Group 1  
(n=34) consisted of children and adults with acute EBV infection based on 
clinical presentation and serological testing. All patients had anti-viral capsid 
antigen (VCA)-specific immunoglobulin M (IgM), anti-VCA-specific IgG, and 
anti-EBV early antigen (EA)-specific IgG. Anti-Epstein Barr nuclear antigen 
(EBNA)-specific antibodies were absent. Group 2 (n= 25) consisted of adults 
without clinical signs of EBV infection. All patients in Group 2 had both anti-
EBNA-specific and anti-VCA-specific IgG antibodies, indicating past EBV 
infection. Group 3 consisted of anti-HIV positive patients (n=25) and Group 4 
consisted of solid organ transplant recipients (n=25). All patients of group 3 
and 4 had both anti-EBNA-specific and anti-VCA-specific IgG antibodies. The 
Group 5 (n=23) consisted of infants without clinical and serological signs of 
past or present EBV infection. 
 
2.4. Statistical Considerations 
 
The median values of positive results of EBV DNA levels in each of the 
patient groups were calculated. For comparative analysis, the Mann-Whitney 
U test was used and a finding of P<0.05 was considered statistically 
significant. 
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3. Results 
 
3.1. Performance of the molecular assay 
Detection of EBV DNA in clinical samples and QCMD 2002 EBV 
proficiency panel was performed with LightCycler EBV Quantification Kit  with 
primers and probes specific for amplification and detection of the EBV DNA. 
When the original samples of QCMD 2002 EBV proficiency panel were 
tested with the LightCycler EBV Quantification Kit, the results obtained from 4 
samples were found to be within ±0.50 log unit of those obtained by reference 
laboratories (Table 1). One sample that contained 1.0 X 103 copies per ml 
showed a 0.58 log unit difference from the expected result. Two samples that 
contained 1.0 X 102 and 5.0 X 102 copies per ml as well as the negative 
control were found to be below the detection limit. 
Linearity was tested with a dilution series of a high-titer EBV DNA routine 
clinical EDTA whole blood sample. A quasilinear curve was observed 
between 1.1 x 103 and 9.5 X 106 copies per ml (Figure 1). 
For determination of interassay variation, the mean EDTA whole blood EBV 
DNA titers ranged from 9.6 X 103 to 2.3 X 104 copies of EBV DNA per ml 
when samples were tested once on each of five different days. Coefficients of 
variation were found to be between 6 and 42%. Intra-assay variation was 
determined by testing four routine clinical samples with mean titers ranging 
from 3.4 X 103 to 2.0 X 104 copies of EBV DNA per ml, five times in one run. 
Coefficients of variation were found to be between 5 and 34% (Table 2). 
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3.2. Quantitation of EBV DNA in Different Groups of Patients 
 
EDTA whole blood EBV DNA levels of patient groups 1 to 5 are shown in 
Figure 2. In patients with acute EBV infection (group 1), the median EDTA 
whole blood EBV DNA load was 1.7 X 104 copies/ml (range, 2.2 x 103 to 1.9 x 
106 copies/ml). Samples of adults with past EBV infection (group 2) tested 
below the lower limit of detection, except of one sample with an EBV DNA 
level of 1.2 X 104 copies/ml. When EDTA whole blood EBV DNA levels of 
anti-HIV antibody positives (group 3) were determined, 9 of 25 (36%) patients 
were found to be below the lower limit of detection. The remaining 16 patients 
were positive for EBV DNA and the median EBV DNA load in these samples 
was found to be 1.6 X 104 copies/ml (range, 8.4 x 103 to 5.0 x 104 copies/ml). 
When EDTA whole blood EBV DNA levels of solid organ transplant recipients 
(group 4) were determined, 15 of 25 (60%) patients were found to be below 
the lower limit of detection. The remaining 10 patients were positive for EBV 
DNA; the median EBV DNA load was found to be 1.0 X 104 copies/ml (range, 
4.5 x 103 to 4.8 x 104 copies/ml). All samples obtained from infants without 
clinical and serological signs of past or present EBV infection (group 5) were 
found to be below the lower limit of detection of the employed molecular 
assay. 
When median EDTA whole blood EBV DNA levels of patients with acute 
EBV infection (group 1) were compared to those of anti-HIV antibody positives 
(group 3) or solid transplant recipients (group 4), no statistically significant 
differences were found (p=0.7399). 
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4. Discussion 
The LightCycler EBV Quantification Kit found to be accurate. For samples 
of an EBV proficiency panel, correct results (i.e., within ± 0.5 log units) were 
obtained except for one result with a slightly increased deviation (+ 0.58 log 
units). According to the manufacturer´s package insert, the lower limit of 
detection is ≤10 copies per reaction (i.e., ≤1000 copies per ml when using 200 
µl of input sample volume and 100 µl of elution volume). Panel samples that 
contained 100 and 500 copies/ml were below the lower limit of detection. 
According to the QCMD 2002 EBV Proficiency Panel Program report, only 3 
of 12 and 4 of 12 laboratories reported correct results for both samples, 
respectively, using this assay (Niesters H., 2003).   
It should be emphasized that this assay allows more reliable and accurate 
EBV DNA quantification when compared to methods targeting the BAMHI-W 
repeats on the EBV genome. 
The linearity was found to be sufficient between 1.1 x 103 and 9.5 X 106 
copies per ml. The interassay variation ranged from 6 to 42% and intra-assay 
variation ranged from 5 to 34%. These results correspond to those reported 
for other molecular assays based on PCR amplification (Kessler et al., 2000; 
Stelzl et al., 2004). 
When the utility of this assay was evaluated on clinical samples, EDTA 
whole blood was taken. Similar to other viruses of the herpesvirus family, EBV 
is associated with cell compartments. EDTA whole blood has been found to 
combine the viral load in both cell and plasma sources and ml of blood is a 
well-standardized unit of sample (Stevens et al., 2001b). Depending on type 
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and stage of disease EBV DNA may also be found in plasma, usually 
representing fragmented cell-derived material. However, during active 
infection EBV DNA can be detected for a longer period of time in whole blood 
than in plasma (Fafi-Kremer et al., 2004).   
EBV DNA was extracted by a standardized, commercially available manual 
protocol. The assay used allows extraction within 45 minutes and is relatively 
easily to handle. With this method, both intra- and extracellular EBV DNA can 
be isolated in a rather simple procedure. 
As expected, all patients with acute infection (group 1) tested positive with 
a relatively wide distribution of EBV DNA values. In group of adults with past 
EBV infection (group 2), no EBV DNA could be detected in EDTA whole 
blood, except of one patient. This patient had CMV infection detected by 
serology just one week earlier, so that CMV infection could have caused T-
cell suppression and EBV reactivation.  
In the group of anti-HIV antibody positive patients without apparent EBV-
related disease (group 3), 16 out of 25 (64%) patients were found to be 
positive for EBV DNA. The corresponding number for solid organ recipients 
(group 4) was 10 out of 25 (40%). In the group of infants without serological 
and clinical signs of acute or earlier EBV infection (group 5), EBV DNA was 
not detected in any of the patients. 
The results for anti-HIV antibody positive patients are in agreement with 
those reported recently (Fafi-Kremer et al., 2004). Similar results were 
obtained when peripheral blood mononuclear cells were tested for EBV DNA 
(Brengel-Pesce et al., 2002). Positive results for EBV DNA may be caused 
indirectly by immunosuppression through either retroviral infection or 
immunosuppressive therapy. In addition, EBV DNA levels in peripheral blood 
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appear to be independent from both CD 4+ T-cell counts and HIV-1 RNA 
levels in plasma. It is documented that elevated EBV DNA is a common 
phenomenon for HIV patients, reflecting rather insufficient immune-mediated 
control of EBV replication then underlying lymphoproliferative disease 
(Stevens et al., 2002a). In organ transplant  recipients, EBV DNA monitoring 
allows early diagnosis of threatening posttransplant lymphoproliferative 
disease, which is preceded by high viral load several months before outbreak 
of disease (Stevens et al., 2001a; Stevens et al., 2002b). Therefore, clinical 
relevance of increased EBV DNA levels in different groups of 
immunocompromised patients may be different.   
On the other hand, single determination of the EBV DNA level has limited 
clinical relevance. Therefore, follow-up of EBV DNA dynamic fluctuations in 
patients with EBV-related diseases would be helpful for the monitoring of 
disease development and therapy response.  
The LightCycler EBV Quantification Kit was found to be useful for 
determination of EBV DNA levels in EDTA whole blood. 
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Tables 
 
Table 1. Results obtained by the LightCycler EBV Quantification Kit in 
comparison with those obtained by reference laboratories with members from 
the Quality Control for Molecular Diagnostics Epstein-Barr Virus Proficiency 
Program Panel 2002. 
 
 
Member 
no. 
Results obtained by 
reference laboratories 
(copies/ml) 
Results obtained by the LightCycler 
EBV Quantification Kit (copies/ml) 
Log unit 
difference 
1 1.0 X 102 UDLa - 
2 0 UDLa - 
3 5.0 X 103 1.4 X 104 +0.45 
4 5.0 X 103 5.7 X 103 +0.06 
5 1.0 X 103 3.8 X 103 +0.58 
6 5.0 X 104 4.7 X 104 -0.03 
7 5.0 X 102 UDLa - 
8 1.0 X 104 1.8 X 104 +0.26 
aUDL, under detection limit
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Table 2. Results of interassay testing (one replicate of each sample was tested 
once on five different days) and  intra-assay testing (five replicates were tested 
in one run). 
 
 
 
 
 
 
 
 
 
 
Interassay variation 
Sample 
no. 
Mean no. of EBV 
DNA (copies/ml) 
Standard deviation Coefficient of variation (%) 
1 9.6 X 103 4.0 X 103 42 
2 1.7 X 104 5.6 X 103 34 
3 1.2 X 104 3.5 X 103 28 
4 1.4 X 104 2.9 X 103 20 
5 1.4 X 104 2.9 X 103 20 
6 1.8 X 104 3.8 X 103 21 
7 2.1 X 104 1.4 X 103 6 
8 2.3 X 104 8.9 X 103 38 
Intra-assay variation 
Sample 
no. 
Mean no. of EBV 
DNA (copies/ml) 
Standard deviation Coefficient of variation (%) 
1 3.4 X 103 1.2 X 103 34 
2 9.5 X 103 4.6 X 102 5 
3 1.2 X 104 1.1 X 103 9 
4 2.0 X 104 3.9 X 103 20 
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Figures 
 
Figure 1. Linearity of the results for a 0.5-log-unit dilution series of a routine 
clinical EDTA whole blood sample with high titer of EBV DNA obtained by the 
LightCycler EBV Quantification Kit. 
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Figure 2. EBV DNA levels (copies/ml) in patients with acute EBV infection 
(group 1), in EBV-seropositive adults without clinical signs of EBV infection 
(group 2), in immunocompromised patients including anti-HIV antibody 
positives (group 3), in solid organ transplant recipients (group 4), and in 
infants without clinical and serological signs of past or present EBV infection 
(group 5). The dashed line indicates the lower detection limit. 
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